Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; indigo carmine aluminium lake; hypromellose; iron oxide yellow; triacetin; iron oxide red; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 2.64 mg (equivalent: prucalopride, qty 2 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; iron oxide yellow; iron oxide red; macrogol 3000; indigo carmine aluminium lake - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - prucalopride succinate, quantity: 1.32 mg (equivalent: prucalopride, qty 1 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; titanium dioxide; hypromellose; triacetin; macrogol 3000 - prucalopride is indicated for the treatment of chronic functional constipation in adults in whom laxatives fail to provide adequate relief. ? before prucalopride is considered patients must have tried at least two different types of laxatives from different classes (at the highest tolerated recommended doses) for at least six months, but have not had adequate relief from constipation. ? if treatment with prucalopride is not effective within four weeks, the benefit of continuing treatment should be reconsidered.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; magnesium stearate; purified talc; lactose monohydrate; colloidal anhydrous silica - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - carbimazole, quantity: 5 mg - tablet - excipient ingredients: croscarmellose sodium; lactose; magnesium stearate - therapy of hyperthyroidism. definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. preparation for thyroidectomy. before and after radioactive iodine treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - carbimazole, quantity: 5 mg - tablet - excipient ingredients: lactose; croscarmellose sodium; magnesium stearate - therapy of hyperthyroidism. definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. preparation for thyroidectomy. before and after radioactive iodine treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - carbimazole, quantity: 20 mg - tablet - excipient ingredients: magnesium stearate; lactose; croscarmellose sodium - therapy of hyperthyroidism. definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. preparation for thyroidectomy. before and after radioactive iodine treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

medtas pty ltd - carbimazole, quantity: 20 mg - tablet - excipient ingredients: lactose; croscarmellose sodium; magnesium stearate - therapy of hyperthyroidism. definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. preparation for thyroidectomy. before and after radioactive iodine treatment.